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ABSTRACT 
DCPS is a candidate cutaneous squamous cell carcinoma (SCC) susceptibility gene as 
determined by allelic imbalance mapping of paired SCC and genomic blood DNA 
samples. DCPS shows no protein expression in 23% of human SCCs on a tissue 
microarray, and reduced protein expression in another 30%.  This is in contrast to 
strong staining for DCPS in 100% of normal tissue samples.  DCPS, a decapping 
scavenger enzyme, influences the pool of available cap-binding proteins and, in turn, 
impacts aspects of mRNA metabolism like pre-mRNA splicing and decay. The 
hypothesis driving this research is that DCPS acts as a tumor suppressor.  To test this 
hypothesis, functional effects of increasing and decreasing expression of DcpS in a 
mouse keratinocyte cell line have been studied.  First intron splicing and exon skipping 
is enhanced in DcpS overexpression cell lines, while splicing of the second intron is not 
affected by DcpS expression.  DcpS knockdown cell lines were found to have more 
stable mRNA compared to a control cell line.  DcpS knockdown cell lines exhibit less 
growth than normal and overexpression cell lines. Cell migration is not affected by DcpS 
expression.  DcpS knockdown cell lines exhibit more apoptosis than normal and 
overexpression cell lines.  Finally, there is a greater percentage of cells in the S and G2-
M phases of the cell cycle in DcpS knockdown cell lines compared to mock and 
overexpression cell lines.  From these studies it appears that while DcpS may affect 
mRNA splicing and stability, decreased levels of DcpS do not result in a cancer 
phenotype.  Rather, decreased levels of DcpS seem to lead to an anti-tumorigenic 
phenotype.  Future directions may include examining the effect of UV radiation on these 
phenotypes and determining other proteins with which DcpS interacts. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cutaneous Squamous Cell Carcinoma (SCC) 
The body’s largest organ, the skin, serves as a barrier to separate internal organs from 
external elements such as heat, light, and numerous pathogens1.  The skin also 
regulates body temperature, stores water and fat, and allows for the sense of touch.   
The skin is composed of three layers: epidermis, dermis, and subcutaneous fat (Figure 
1).  The epidermis is the thin outer layer of skin, which consists of five layers of cells in 
order from deep to superficial: stratum basale, stratum spinosum, stratum granulosum, 
statum lucidum, and stratum corneum.  The germinal cells needed for regeneration of 
the epidermis originate in the stratum basale and undergo a progressive maturation 
called keratinization as they migrate to the surface. 
 
The dermis is located between the epidermis and the layer of subcutaneous fat layer1.  
This layer contains blood vessels, lymph vessels, hair follicles, sweat glands, collagen 
bundles, fibroblasts, and nerves.  The dermis also contains specialized cells and 
structures including sebaceous glands and apocrine glands, eccrine glands, Meissner’s 
and Vater-Pacini corpuscles, and pain and touch receptors. 
 
The deepest layer of the skin is the layer containing subcutaneous fat1.  It consists of a 
network of collagen, connective tissue, and fat cells that help conserve the body’s heat 
and protect the body from injury by acting as a shock absorber.  This layer also houses 
larger blood vessels and nerves. 
8 
The two broad categories of skin cancer are melanoma and nonmelanoma skin cancer.  
Melanoma skin cancer results when melanocytes, the pigment producing cells, become 
malignant.  Nonmelanoma skin cancer (NMSC) results from tumorigenesis of the 
epidermis and includes basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC)2.  This research focuses on squamous cell carcinoma.  Cutaneous squamous 
cell carcinoma is a malignant tumor of keratinocytes in the upper layer of the 
epidermis3. 
 
Skin cancer is the world’s most common cancer with more new cases annually than the 
combined incidences of cancers of the breast, prostate, lung, and colon4.  There has 
been more than a 300 percent increase in non-melanoma skin cancer cases in the 
United States since 19944.  People who have had non-melanoma skin cancer have 
twice the risk of developing other malignancies.  Squamous cell carcinoma is the 
second most common form of skin cancer, equating to 700,000 cases diagnosed 
annually resulting in approximately 2,500 deaths. 
 
Cutaneous squamous cell carcinoma typically presents clinically as a new or growing 
lesion on the skin3.  Tumors appear as raised, ulcerous, papules that may bleed, weep, 
and be painful or tender3,5.  SCC is caused by ultraviolet radiation and most commonly 
occurs on the arms, legs, nose, and ears since these are the parts of the body most 
often exposed to the sun6.  Other SCC risk factors include old age, smoking, human 
papilloma virus infection, chronic inflammation of the skin, being male, having light skin, 
exposure to chemical carcinogens, and immunosuppression3,5. 
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1.2 Identification of DcpS as a candidate SCC susceptibility gene 
DcpS is a candidate squamous cell carcinoma (SCC) susceptibility gene as determined 
by allelic imbalance mapping of SCC and genomic blood DNA samples obtained from 
65 organ transplant patients7. Organ transplant patients tend to develop multiple tumors 
as a result of immunosuppression.  Having multiple tumors linked to the same genomic 
blood DNA is important in the study of preferential allelic imbalance because it allows 
for determination of whether a certain allele is lost in the tumors. 
 
Array Comparative Genomic Hybridization (aCGH) was used to determine 
chromosomal gains and losses in SCCs and frequency plots of these changes were 
mapped in over 300 SCCs7. Forty-five microsatellite markers were used to examine the 
14 chromosomal regions showing frequent losses and gains by aCGH.  Thirteen of 
these markers were shown to exhibit preferential allelic gains or losses in tumor/normal 
pairs. A few loci showing evidence of preferential allelic imbalance in tumors were 
targeted for higher-resolution studies to identify candidate single nucleotide 
polymorphisms (SNPs) driving allele-specific imbalance.  SNPs mapping to a small 
region of about 100kb on 11q24 showed strong evidence (p<0.005) of preferential allelic 
loss. This region contains three genes: DCPS, TIRAP, and ST3GAL4. 
 
DCPS was chosen to be the focus of this study because no DCPS protein expression 
was seen in 23% of human SCCs on a tissue microarray and another 30% showed 
decreased expression7.  All normal skin samples showed strong nuclear DCPS staining. 
The expression pattern for ST3GAL4 was not as consistent.  Human SCC samples had 
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similar staining patterns to normal tissue.  A loss of ST3GAL4 protein expression was 
only detected in 2% of the samples.  Protein expression of TIRAP was not examined in 
human SCC samples due to a lack of antibody that would bind TIRAP specifically. 
 
1.3 DcpS Functions 
DcpS, a decapping scavenger enzyme, has been shown to influence the pool of 
available cap-binding proteins and, in turn, impact downstream aspects of mRNA 
metabolism like pre-mRNA splicing, mRNA decay, nuclear export, and translation8.  The 
role that DcpS has been shown to have in first intron pre-mRNA splicing provides a link 
between splicing and decay9.  Human mRNA translation start sites are found in the first 
exon.  The first intron commonly contains a premature translation termination codon, so 
if it is not spliced from the mRNA the nonsense-mediated mRNA decay surveillance 
pathway will lead to rapid degradation.  When there are normal levels of DcpS in the 
cell, cap-binding complex (CBC) binds to the cap on the 5’ end of mRNA to facilitate 
removal of the first intron by enhancing assembly of the splicosome8 (Figure 3).  Low 
DcpS levels lead to low splicing efficiency because DcpS regulates the active pool of 
CBC through hydrolysis of free cap structures.  Free cap structures that are not 
attached to mRNA occupy the CBCs, inactivating them.  This prevents the CBC from 
being available to bind to a cap structure that is attached to mRNA and promoting 
splicing.  This was observed in rat fibronectin mini-gene mRNA as well as two multi-
exon endogenous genes. As many cancers show aberrant RNA splicing, this is one 
potential mechanism by which DcpS might influence tumorigenesis. 
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Studies on DCS1, an orthologous gene to DcpS in yeast, have shown that disruption of 
the gene leads to a decrease in mRNA decay8.  This effect has been rescued by 
exogenous expression of DCS1p, a gene with a similar function.  Since the presence of 
DSC1p promotes decay, the cytoplasmic exoribonuclease, Xrn1p, that is responsible for 
the decay of decapped mRNAs seems to be the most likely target of regulation.  Two 
theories regarding the mechanism of action have been suggested: cap structures inhibit 
exoribonuclease activity, or the hydrolyzed products have a stimulatory effect on 
exoribonuclease activity.  Previously, the effect of DCPS on mRNA decay in mammalian 
cells had not been tested. 
 
DcpS also plays a role in nuclear export through regulation of the active pool of CBC, 
which stimulates nuclear export8.  Nuclear export is more efficient with higher levels 
DcpS.  Nuclear export is important because if there is nuclear mRNA retention, there is 
a reduced pool of cytoplasmic mRNA available for translation.  Further evidence for 
DcpS as a nucleocytoplasmic shuttling protein is provided by the fact that according to 
fluorescence studies DcpS is primarily found in the nucleus; however, it has also been 
isolated from the cytoplasm.  DcpS contains a nuclear export signal (NES), a leucine 
rich region at the central hinge of the protein, and a nuclear localization signal (NLS), a 
stretch of basic amino acids. 
 
Finally, DcpS affects translation by preventing the translation initiation factor eIF4E from 
being sequestered by free cap structures8.  DcpS allows eIF4E to bind to 5’ cap 
structures that are bound to mRNA and promote translation.  DcpS will displace eIF4E 
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bound to cap structure but will not displace eIF4E from capped mRNA.  This means that 
DcpS does not impede translation. 
 
1.4 Hypothesis and Specific Aims 
The central hypothesis driving this research is that DcpS acts as a tumor suppressor in 
cutaneous squamous cell carcinoma through its role in pre-mRNA splicing and/or 
mRNA stability.  To test this hypothesis, functional differences that occur when DcpS 
expression is varied in a normal mouse keratinocyte cell line will be tested. 
1. Determine whether differences in DcpS expression lead to changes in mRNA 
splicing and stability, which are potential mechanisms of tumorigenesis. 
2. Determine whether differences in DcpS expression lead to functional changes in 
common cancer phenotypes such as cell proliferation, apoptosis, cell migration, 
and cell cycle stage. 
 
A gene is considered a tumor suppressor if its loss or inactivation results in an abnormal 
growth of tissue10. When present at normal expression levels, tumor suppressor genes 
help regulate normal cell processes, but when they are lost or inactivated their 
protective effect against cancer is decreased.  The decreased expression of DcpS in 
human SCC samples compared to normal tissue, alongside the preferential allelic 
imbalance data led to the hypothesis that DcpS acts as a tumor suppressor in 
cutaneous squamous cell carcinoma. 
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Previous research has shown that human mRNA translation start sites are found in the 
first exon of genes11.  DcpS preferentially affects splicing of the first intron, and the first 
intron commonly contains a premature translation termination codon8,12,13.  If the first 
intron is not spliced from the mRNA the nonsense-mediated mRNA decay surveillance 
pathway will lead to rapid degradation.  Aberrant splicing has been associated with 
numerous cancers including lung cancer, gastric cancer, breast cancer, melanoma, and 
cutaneous T-cell lymphoma14.  Altering splicing efficiency of the first intron will lead to 
abnormal degradation of gene products, thereby altering their expression levels.  
Therefore, affecting pre-mRNA splicing is a potential mechanism by which DcpS may 
influence tumorigenesis.  DcpS may also regulate gene expression and the 
development of cancer through its effects on mRNA stability.  Studies on DCS1, an 
orthologous gene to DcpS in yeast, have shown that disruption of the gene leads to a 
decrease in mRNA decay15.  If mRNA remains in the cell for an abnormal amount of 
time, it will be available for translation for an abnormal amount of time, ultimately 
leading to abnormal protein levels. 
 
In addition to determining the method by which DcpS may affect tumorigenesis, it is 
important to examine how changes in pre-mRNA splicing and mRNA stability relate to 
the function of the cells.  Cancer cells frequently exhibit phenotypes such as 
uncontrolled proliferation, decreased apoptosis, de-regulated cell cycles, increased 
migration, increased invasion, and increased metastasis10. These phenotypes lead to 
the development of tumors.  Since these are common cancer phenotypes, I examined 
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the effects of varying levels of DcpS expression on cell proliferation, apoptosis, cell 
migration, and cell cycle. 
 
 
FIGURE 1. Schematic drawing of normal skin including skin layers (epidermis, dermis,  
and subcutaneous fat) and structures located in the skin19. 
 
 
 
FIGURE 2. Map of 11q24, the minimal candidate region identified by Dworkin et all7. 
 
 
15 
 
 
FIGURE 3. Mechanism by which DcpS influences pre-mRNA splicing efficiency.  DcpS modulates the 
pool of active Cap Binding Complex (CBC).  Active CBC binds to the 5’ mRNA cap and facilitates 
assembly of the spliceosome at the 5’ splice site of the first intron, leading to high splice efficiency.  The 
CBC is not available to do so when it is inactivated by free cap structures8.
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell Lines 
All experiments were performed using an immortalized normal murine keratinocyte cell 
line, C5N, which was obtained from Allan Balmain16.  This cell line was directly derived 
from normal mouse skin.  It is immortalized, but non-tumorigenic. Cells were grown in 
Dulbecco’s modifications of Eagle’s medium (DMEM, Cellgro) supplemented with 10% 
fetal bovine serum (GIBCO, Invitrogen) and 1% penicillin streptomycin (Invitrogen). 
 
2.2 Transfection 
Transfections were performed using Lipofectamine. The transfections for transient DcpS 
overexpression using the DcpS mouse cDNA clone (OriGene), pCMV6-Kan/Neo, were 
performed according to the Lipofectamine protocol in a final volume of 5 mL of OPTI-
MEM in a 10 cm dish (Invitrogen). C5N cells were plated prior to transfection in a 10 cm 
dish. Cells were transfected at 70% confluency. 
 
2.3 Lentiviral Transduction 
Lentiviral transduction was used to make stable DcpS knockdown cell lines.  The 
293RTV cell line was used to grow the virus (Cell Biolabs).  This cell line is a permanent 
line established from primary embryonic human kidney and transformed with human 
adenovirus type 5 DNA.  Four different mouse pLKO.1 shRNA constructs against DcpS 
were used separately and in combination to achieve knockdown (Open Biosystems).  
The packaging plasmid, pCMV-dR8.2, and the envelope plasmid, pMD2.D, were also 
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transfected (addgene).  Transfections with DcpS shRNAs were performed according to 
the FuGENE 6 protocol (Roche) in a final volume of 4 mL of Dulbecco’s modifications of 
Eagle’s medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum (GIBCO, 
Invitrogen) and 1% penicillin streptomycin (Invitrogen) in a 6cm dish.  293RTV cells 
were plated prior to transfection in the 6cm dish.  Cells were transfected at 70% 
confluency.  After incubating cells for 18 hours (37C, 5% CO2) media was changed to 6 
mL high serum growth media (30% FBS).  Viral supernatant was collected over the next 
30 hours.  C5N cells plated in 6 mL complete media in 6cm dishes were treated with 
viral supernatant at 70% confluency.  Puromycin (Enzo Life Sciences) selection was 
begun 32 hours post-infection at a concentration of 1.5ug/mL.  12 days post-selection 
antibiotic, Puromycin concentration was reduced to 0.75ug/mL. 
 
2.4 Pre-mRNA Splicing 
DcpS overexpression, knockdown, and mock cell lines were transfected with a mini-
gene construct, pCMV2B MDM2 3-11-1220, according to Lipofectamine protocol 
(Invitrogen).  Whole-cell RNA was extracted from cells and reverse transcribed into 
cDNA.  Primers specific to the mini-gene were used to amplify cDNA, which was then 
analyzed using gel electrophoresis.  The amount of each splicing product was 
quantitated using Alpha Imager. 
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FIGURE 4. Diagram of pCMV2B MDM2 3-11-12 mini-gene construct, including number 
of base pairs in each intron and exon20. 
 
2.5 mRNA Stability 
A DcpS knockdown cell line and overexpression cells, forty-eight hours after 
transfection, were treated with actinomycin D and alpha-amanitin, to prevent RNA 
production, and were harvested at 0, 2, 4, 8, and 24 hours. Whole-cell RNA was 
extracted from cells and reverse transcribed into cDNA.  RT-qPCR was used to 
measure mRNA levels of 4 genes, Ahr (2.51h half-life), Twistnb (3.03h half-life), Hprt1 
(8.46h half-life), and Ppia (9.19h half-life)21.  mRNA levels at each time point were 
calculated as a percentage of mRNA at t=0 treated. 
 
2.6 Cell Proliferation 
One day post-transfection, DcpS overexpression cells and a DcpS knockdown cell line 
in 10 cm dishes were scraped, and cells were replated in quadruplicate into a 96 well 
dish. Proliferation was measured at 24, 48, and 72 hours post-transfection using the 
MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Cell Proliferation Kit 
I according to manufacturer’s instructions (Roche). The cells were solubilized four hours 
after the addition of the MTT reagent using the kit’s provided solubilization reagent. The 
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solution was then incubated for 24 hours, and absorbance was then measured at 550 
nm using a spectrophotometer. 
 
2.7 Apoptosis 
Apoptosis of experimental cell lines was determined using flow cytometry.  Cells were 
treated with 0.05% EDTA (Ethylenediaminetetraacetic acid) and 0.1% trypsin, 
separated into single cells using filters, washed with PBS, and resuspended in 1x 
Binding Buffer at a concentration of 2 x 106 cells/mL.  Cells were stained with FITC 
Annexin-V and Propidium iodide.  Annexin-V is used to detect the presence of a marker 
of early apoptosis.  Propidium iodide is used to visualize DNA in the nucleus, and is 
therefore a marker of late apoptosis.  Samples were analyzed by fluorescence activated 
cell sorting (FACS). 
 
2.8 Cell Migration 
DcpS overexpression, knockdown, and mock cell lines were plated in migration wells, 
which create a cell-free gap, as in scratch assays, of approximately 500 um at a 
concentration of 7 x 105 cells/mL (ibidi).  70 uL of this solution was placed in each well 
and incubated overnight at 37C and 5% CO2.  Migration wells were then removed and 
cells were able to fill the cell-free gap.  Migration was monitored at approximately 0, 12, 
and 24 hours. 
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2.9 Cell Cycle Stage 
Cell cycle stage of experimental cell lines was determined using flow cytometry 48 after 
transfection.  Cells were treated with 0.05% EDTA and 0.1% trypsin, separated into 
single cells using filters, washed with PBS, and resuspended in cold 70% ethanol. 
RNAase A was added to remove any residual RNA. The DNA was stained with 
propidium iodide, in order to visualize DNA content, and therefore the cell cycle stage. 
Samples were analyzed by FACS. 
 
2.10 Quantitative Real-Time PCR 
Whole-cell RNA was extracted from experiments using RiboZol Extraction Reagent 
(AMRESO).  cDNA was generated from extracted RNA using the I-Script kit according 
to manufacturer’s protocol (BioRad). Transfection efficiency was verified by measuring 
DcpS expression at experimental timepoints post-transfection using quantitative real-
time PCR (qPCR). 
 
Taqman qPCR was performed in triplicate according to manufacturer’s protocol to 
measure DcpS expression (Applied Biosystems). DcpS expression was presented as a 
percent relative expression to Gapdh expression using the ΔCT equation (equation: 
(2^X)*100 where x= control gene expression-target gene expression). Probes were 
obtained via Applied Biosystems. 
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2.11 Western Blotting 
Protein was extracted at experimental timepoints via solubilization of the cells in RIPA 
buffer (50 mM Tris base pH 8, 150 mM NaCl, 1% NP40, 0.10% SDS) and subsequent 
removal of the supernatant (20 uL). Equal amounts of protein (30 ug each) were 
separated by 10% SDS-PAGE and then transferred to nitro-cellulose membrane. The 
membranes were blocked with a buffer containing 5% nonfat milk in phosphate-buffered 
saline with 0.05% Tween 20 for 30 min and incubated overnight with a 1:200 dilution of 
DcpS primary antibody (Santa Cruz Biotechnology).  After 3 washes with phosphate-
buffered saline with 0.05% Tween 20, the membranes were incubated with an anti-
mouse secondary antibody for 2 hours.  α-tubulin (Santa Cruz Biotechnology) was used 
as a loading control. 
 
2.12 Calculations and Statistical Significance 
Averages and standard deviations were determined for experimental and control 
variables using Microsoft Excel. A two-tailed student’s t-test was used to determine 
significance. Differences between variables were considered significant if p<0.05. 
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2.13 Primers: Table 1 
Amplified DNA Forward Reverse 
MDM2 mini-gene intron 1 5’ GAT TAC AAG GAT GAC GAT AAG 3’ 5’ CCC TGC CTG ATA CAC AGT A 3’ 
MDM2 mini-gene intron 2 5’ GTT ACT GTG TAT CAG GCA GG 3’ 5’ CAA TCA GGA ACA TCA AAG CC 3’ 
p53 mini-gene intron 1 5’ GAT TAC AAG GAT GAC GAT AAG 3’ 5’ CGG AGA TTC TCT TCC TCT GT 3’ 
p53 mini-gene intron 2 
5’ AGC TTT GAG GTG CGT GTT TGT 
GCC T 3’ 
5’ CCC TCG AGC TGA AGG GTG AAA 
TAT TCT CCA TCC 3’ 
 
TABLE 1. Primer sets used for PCR amplification in pre-mRNA splicing experiments20.
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CHAPTER 3 
RESULTS 
3.1 DcpS enhances pre-mRNA splicing 
To determine if DcpS affects pre-mRNA splicing in mammalian keratinocytes, an MDM2 
mini-gene was transfected into DcpS overexpression, DcpS knockdown, and mock C5N 
cell lines.  Splicing products were quantified using Alpha Imager (Figure 5).  The first 
intron was retained in 13.84% of splicing product from the mock cell line and 7.07% of 
splicing product from the DcpS overexpression cell line (Figure 5A).  A similar trend of 
decreased intron retention in DcpS overexpression cell lines was observed in 4/4 
experimental replicates.  The second intron was retained in 39.43% of mock cell line 
splicing product and 37.89% of DcpS overexpression splicing product (Figure 5B).  3/3 
experimental replicates showed similar findings.  38.81% exon skipping was observed 
in DcpS overexpression cell lines compared to 20.95% exon skipping in the mock cell 
line (Figure 5C).  This trend was observed in 3/3 repeats of the experiment.  Splicing 
results of the first intron, second intron, and exon skipping for DcpS knockdown cell 
lines compared to mock were highly variable.  Overall, there is approximately 61.63% 
removal of both introns in mock cell lines, compared to 65.30% removal of both introns 
in the DcpS knockdown cell line (Figure 5D).  These results suggest that increased 
DcpS enhances splicing of the first intron and exon skipping, while splicing of the 
second intron is not affected. 
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FIGURE 5A. Above: Diagram of the splicing product that is quantified in this figure. 
Below: Splicing of the first intron was measured in DcpS overexpression (over) and mock cell lines by 
quantifying cDNA amplified using primers specific for the first intron of the mini‐gene. 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FIGURE 5B. Above: Diagram of the splicing product that is quantified in this figure. 
Below: Splicing of the second intron was measured in DcpS overexpression (over) and mock cell lines by 
quantifying cDNA amplified using primers specific for the second intron of the mini‐gene. 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FIGURE 5C. Above: Diagram of the splicing product that is quantified in this figure. 
Below: Exon skipping was measured in DcpS overexpression (over) and mock cell lines by quantifying 
cDNA amplified using primers that spanned the entire mini‐gene. 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FIGURE 5D. Above: Diagram of the splicing product that is quantified in this figure. 
Below: The effect of DcpS knockdown (KD) on splicing was measured by quantifying cDNA amplified 
using primers spanning the entire mini‐gene. 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3.2 Loss of DcpS increases stability of mRNA 
To determine if the amount of DcpS in a cell influences the stability of mRNA, DcpS 
overexpression, DcpS knockdown, and mock C5N cell lines were treated with 
Actinomycin D and alpha-amanitin to stop the production of mRNA.  RNA from genes 
with short and medium length half-lives was then measured at 0, 2, 4, 8, and 24 hours 
after treatment using RT-qPCR (Figure 6).  Ahr (2.51h half-life)21 had significantly more 
mRNA 4 and 8 hours after treatment in a DcpS knockdown cell line compared to mRNA 
levels in mock and DcpS overexpression cell lines (p < 0.05; Figure 6).  Hprt1 (8.46h 
half-life)21 had significantly more mRNA 2, 4, 8, and 24 hours after treatment in a DcpS 
knockdown cell line compared to mRNA levels in mock and DcpS overexpression cell 
lines (p < 0.05; Figure 6).  Significance at the 24-hour time point was not repeated in 4/6 
experiments.  Ppia (9.19h half-life)21 mRNA showed similar trends to those illustrated 
with Ahr and Hprt1.  These results suggest that DcpS knockdown increases mRNA 
stability, particularly at early time points of the experiment. 
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FIGURE 6. Ahr and Hprt1 mRNA stability was measured via RT-qPCR at 0, 2, 4, 8, and 24 hours in DcpS 
overexpression (over), DcpS knockdown (KD), and mock C5N cell lines.  mRNA stability was measured in 
triplicate.  *p < 0.05.  **p < 0.01.  #p < 0.01, significance was not detected in experimental replicates. 
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3.3 Loss of DcpS reduces cell proliferation 
To determine if DcpS affects cell proliferation, DcpS overexpression, DcpS knockdown, 
and mock C5N cell lines were used to measure cell proliferation at 24, 48, and 72 hours 
post transfection via an MTT assay (Figure 7).  A significant decrease in growth rate 
(slope) was observed from 24 to 72 hours in DcpS knockdown cells compared to the 
mock and DcpS overexpression cell lines (p < 0.01; Figure 7).  Specifically, a significant 
decrease in growth rate (slope) was observed from 24 to 48 hours in DcpS knockdown 
cells compared to the mock and DcpS overexpression cell lines (p <0.01; Figure 7). The 
difference in growth rate (slope) from 48 to 72 hours between DcpS knockdown cells 
compared to the mock was not significant (p=0.062).  Similar results were observed in 
two out of three total experiments. These results suggest DcpS knockdown reduces cell 
proliferation. 
 
FIGURE 7. Cell proliferation (Absorbance 550nm) was measured via an MTT assay at 24, 48, and 72 
hours in DcpS overexpression (triangle), DcpS knockdown (square), and mock (diamond) C5N cell lines.  
Proliferation at each time point was measured in quadruplicate.  **p < 0.01. 
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3.4 DcpS does not affect cell migration 
To determine whether DcpS affects cell migration, DcpS overexpression, DcpS 
knockdown, and mock C5N cell lines were plated in migration wells, which created a 
cell-free gap as in a scratch assay (Figure 8).  Pictures were taken of cells 
approximately every 12 hours to monitor migration of cells towards closing the gap.  
Using this method, no consistent difference in cell migration between cell lines could be 
detected.  In two out of four total experiments no difference was detected.  In one out of 
four experiments, DcpS knockdown cells demonstrated faster migration.  In one out of 
four experiments, DcpS overexpression cells showed faster migration. 
 
FIGURE 8. Cell migration was monitored at approximately 0, 12, and 24 hours via scratch assay in DcpS 
overexpression (over), DcpS knockdown (KD), and mock C5N cell lines.  Shown here are representative 
pictures of the migration observed. 
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3.5 Loss of DcpS induces apoptosis 
To determine if DcpS affects apoptosis, DcpS overexpression, DcpS knockdown, and 
mock C5N cell lines were stained with FITC Annexin-V and propidium iodide then 
analyzed by FACS (Figure 9).  A significant increase in apoptosis was observed in 
DcpS knockdown cells compared DcpS overexpression and mock cell lines (p < 0.05; 
Figure 9). These results suggest DcpS induces apoptosis, which, in part, may account 
for the observed decrease in cell proliferation.  Four DcpS knockdown cell lines 
generated using shRNAs targeted to different regions of DcpS were tested.  Three of 
the four stable DcpS knockdown cell lines consistently showed a trend of increased 
apoptosis. 
 
FIGURE 9. Apoptosis (stained with FITC Annexin-V and Propidium Iodide) was measured via flow 
cytometry using mock, DcpS overexpression (over), and DcpS knockdown (KD) C5N cell lines. 
Apoptosis was measured in triplicate. *p < 0.05. 
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3.6 Loss of DcpS increases the percentage of cells in S phase and G2-M phase 
To determine if DcpS affects cell cycle stage, DcpS overexpression, DcpS knockdown, 
and mock C5N cell lines were stained with propidium iodide to visualize DNA content 
and analyzed by FACS 48 hours after transfection (Figure 10).  A significant increase in 
the percentage of cells in S phase was observed in DcpS knockdown cells compared 
DcpS overexpression and mock cell lines (p < 0.01; Figure 10).  There was also a 
significant increase in the percentage of cells in G2-M phase of the cell cycle in DcpS 
knockdown cells compared DcpS overexpression and mock cell lines (p < 0.01; Figure 
10).  Out of three experimental replicates using four DcpS knockdown lines generated 
using different shRNAs, increased S and G2-M phase was seen in 6/12, no change was 
observed in 4/12, and 2/12 showed a decreased percentage of cells in the S and G2-M 
cell cycle stage.  Figure 10 shows a significant decrease in the percentage of cells in 
both S phase and G2-M phase in DcpS overexpression cells compared to a mock cell 
line (p < 0.05; Figure 10).  This result was not detected in 2/3 experimental replicates. 
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FIGURE 10. Cell cycle stage (stained with Propidium Iodide) was monitored via flow cytometry using 
mock, DcpS overexpression (over), and DcpS knockdown (KD) C5N cell lines. 
Cell cycle stage was measured in triplicate. **p < 0.01.  #p < 0.05, significance was not detected in 
experimental replicates.
35 
CHAPTER 4 
DISCUSSION 
We hypothesized that DcpS acts as a tumor suppressor in cutaneous squamous cell 
carcinoma through its effects on pre-mRNA splicing and mRNA stability.  Furthermore, 
we tested the effects of increasing and decreasing the expression of DcpS on common 
cancer phenotypes such as cell proliferation, apoptosis, cell migration, and cell cycle 
stage to determine functional differences of altered DcpS expression.  In summary, 
there were two aims to this study: 
1. Determine whether differences in DcpS expression lead to changes in mRNA 
splicing and stability, which are potential mechanisms of tumorigenesis. 
2. Determine whether differences in DcpS expression lead to functional changes in 
common cancer phenotypes such as cell proliferation, apoptosis, cell migration, 
and cell cycle stage. 
 
4.1 DcpS alters pre-mRNA splicing and mRNA stability 
Based on our results, DcpS overexpression transfection results in enhanced splicing of 
the first intron of the MDM2 mini-gene as well as increased exon skipping of the MDM2 
mini-gene.  DcpS knockdown cell lines did not alter splicing of the mini-gene compared 
to a mock cell line.  In addition, we have shown increased mRNA stability with DcpS 
knockdown of the genes Ahr, Ppia, and Hprt1, particularly at early time points.  DcpS 
overexpression was not determined to have an effect on mRNA stability.  These results 
together suggest DcpS may be regulating protein levels in the cell through two potential 
mechanisms. 
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Previous studies have shown that DcpS knockdown decreased splicing efficiency of the 
first intron of a rat fibronectin mini-gene mRNA as well as two multi-exon endogenous 
genes8.  While we did not see these effects with DcpS knockdown, we did show that 
increasing DcpS affects splicing of the first intron.  We may not have seen effects with 
DcpS knockdown because the published study achieved greater than 90% knockdown, 
while the knockdown cell lines used in this study have 50-60% knockdown of DcpS.  
There may also be a cell-line specific component to the splicing effect that contributed 
to the difference in results, since human embryonic kidney cells were used previously 
and this study is examining mouse keratinocytes.  A further limitation of this study is the 
fact that it is not known whether there is a particular family of genes that is affected by 
DcpS, while others are not as affected.  If genes that are unaffected by DcpS are 
chosen for study, the true effect of DcpS on pre-mRNA splicing within the cell will not be 
realized.  Pre-mRNA splicing may influence protein levels because human mRNA 
translation start sites are commonly found in the first exon9.  The first intron commonly 
contains a premature translation termination codon, so if it is not spliced from the mRNA 
the nonsense-mediated mRNA decay surveillance pathway will lead to rapid 
degradation.  Based on the enhancement of splicing observed with DcpS 
overexpression, it seems clear that DcpS influences pre-mRNA splicing. 
 
The mRNA stability results obtained in this study are consistent with a previous study 
conducted on an orthologus gene, DCS1, in yeast15.  This study showed that disruption 
of the gene leads to an increase in mRNA stability, just as this study demonstrated that 
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DcpS knockdown lead to more stable mRNA.  This indicates that this gene plays a role 
in mRNA stability in both non-mammalian and mammalian systems.  It had not 
previously been established that DcpS may have a greater effect on mRNA stability at 
earlier time points.  This suggests that there are other proteins involved in the stability of 
mRNA at later time points.  This study was limited by not having an internal control gene 
for RT-qPCR to which the test genes could be normalized.  Since all mRNA production 
is stopped in the cell by Actinomycin D and alpha-amanitin, all mRNA will experience 
some degradation.  An alternative to using mRNA to normalize to is to use ribosomal 
RNA (rRNA) such as 18S.  This approach was attempted however; Actinomycin D 
inhibits the production of rRNA.  mRNA production was not shown to be inhibited using 
alpha-amanitin alone, so it was necessary to use it in conjunction with Actinomycin D.  
Changes in mRNA stability may influence protein levels because mRNA transcripts are 
present in the cell for abnormal amounts of time.  This means they are available for 
translation for an abnormal amount of time, leading to disregulated protein levels. 
 
In regard to the effects of DcpS on both pre-mRNA splicing and mRNA stability, it will be 
important to determine whether DcpS has a global affect, or if there is a specific subset 
of genes that DcpS affects preferentially.  For pre-mRNA splicing this may be 
accomplished by using a microarray in which there is a “common” probe that 
determines whether a gene is expressed, and an “isoform-specific” splice junction and 
exon probe set to distinguish alternative mRNA isoforms17.  This would be used to 
measure differences in the abundance of different isoforms in DcpS overexpression, 
DcpS knockdown, and mock C5N cell lines and to determine which genes DcpS affects.  
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Alternatively, RNA-seq libraries generated from DcpS overexpression, DcpS 
knockdown, and mock C5N cell lines may be used to determine whether there are 
splicing differences between cell lines with different levels of DcpS.  Analysis of this 
data will yield information about how the splicing of all transcribed genes varies as 
levels of DcpS change. 
 
Similar results may be obtained for mRNA stability by incubating experimental cell lines 
in growth media containing 4-thiouridine, which is incorporated into cellular RNA18.  4-
thiouridine-labelled transcripts would then be removed from 4-thiouridine containing 
growth media and quantified at different time points.  A relative decay rate can be 
calculated for each transcript based on the rate at which the 4-thiouridine labeled 
transcripts, in the absence of 4-thiouridine media, are replaced by newly synthesized 
unlabelled mRNAs. 
 
4.2 DcpS Affects Common Cancer Phenotypes 
Based on our results, DcpS knockdown using an shRNA results in a decrease in growth 
rate between 24 and 48 hours in DcpS knockdown cells compared to mock and DcpS 
overexpression cell lines.  In addition, apoptosis was significantly increased in DcpS 
knockdown cells compared to mock and DcpS overexpression cell lines.  This suggests 
that a decrease in DcpS, at least in part, may be decreasing cell proliferation by 
inducing apoptosis.  Cell cycle analysis showed that DcpS knockdown lead to a 
significant increase in the percentage of cells in S phase and G2-M phase, meaning that 
more cells are synthesizing DNA and dividing.  Combined with the cell proliferation and 
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apoptosis findings, this suggests that with a loss of DcpS more cells are trying to grow, 
but they are undergoing apoptosis, which ultimately leads to a decrease in cell 
proliferation.  This is opposite what we would have expected to find if DcpS were acting 
as a tumor suppressor as originally hypothesized.  If this were the case, we would have 
expected DcpS knockdown to ultimately increase cell proliferation, likely by decreasing 
apoptosis and increasing the percentage of dividing cells.  Knockdown of DcpS may 
have the observed phenotype because it is not the gene at 11q24 driving susceptibility 
to SCC, because DNA damage is required to see tumorigenic effects, because DcpS 
works with another protein that must be lost or mutated to lead to the development of 
cancer, or DcpS is involved with tumor progression rather than initiation. 
 
While consistent differences in cell migration due to DcpS expression were not detected 
in this study, a more sensitive screen has the potential to reveal such effects.  Changing 
the observation interval from 12 hours to something shorter such as 3 hours or 
continuous monitoring would be the best way to detect changes in cell migration due to 
DcpS levels, since there does not seem to be any gross abnormalities.  Alternatively, 
cell migration may be studied by plating experimental cell lines on fibronectin-coated 
membranes and allowing them to migrate for 6 or 12 hours.  Following migration, cells 
would be fixed, crystal violet stained, and cells on the top of the membrane would be 
removed.  Sorenson’s buffer would be added to the migrated cells to release crystal 
violet staining and absorbance of the stain would be measured by luminometer. Cell 
migration levels of each of the experimental cell lines would be compared based on 
absorbance. 
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4.3 Future Studies and Conclusion 
Based on the results of this study and the fact that there are other genes in the 11q24 
region that are also candidate susceptibility genes, it is unlikely that DcpS is a 
susceptibility gene for cutaneous squamous cell carcinoma. However, the possibility 
remains that DcpS is acting in conjunction with other factors to lead to the development 
of SCC. 
 
One of these factors contributing to the development of SCC may be exposure to UV 
radiation or other carcinogens.  A future study to address this possibility would be to 
expose samples to UV radiation prior to conducting experiments on the common cancer 
phenotypes discussed here: cell proliferation, apoptosis, cell migration, and cell cycle 
stage.  There may be new or more significant differences between DcpS 
overexpression, DcpS knockdown, and mock C5N cell lines in this circumstance. 
 
Another possibility is that DcpS interacts with one or more additional proteins to lead to 
the developments of SCC.  In this case, the interacting proteins may need to be lost or 
mutated in addition to a loss of DcpS in order to observe the cancer phenotype.  
Proteins that directly interact with DcpS may be determined through a co-
immunoprecipitation experiment in which antibody would be used against DcpS with the 
hope of isolating a larger interacting complex.  In order to examine a panel of genes that 
may be affected by DcpS expression, but not necessarily directly interacting with DcpS, 
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would require the use of a microarray experiment comparing differences between gene 
expression levels in DcpS overexpression, DcpS knockdown, and mock C5N cell lines. 
 
Finally, DcpS may be involved with the progression of tumors, rather than in their 
initiation.  In order to further examine this possibility, it would be necessary to use an in 
vivo model of SCC.  Using this model, DcpS expression could be monitored throughout 
the progression and development of a tumor.  In addition, after the initiation of tumors, 
DcpS could be added or removed and the effect could be observed.  Mice who are 
heterozygous for DcpS or mice that have DcpS knocked out selectively in keratinocytes 
could also be used to study the role of DcpS in SCC. 
 
In conclusion, I have found that DcpS seems to affect pre-mRNA splicing and mRNA 
stability.  These findings confirm results that had been seen previously by other 
studies9,15.  However, while DcpS does affect pre-mRNA splicing and mRNA stability, it 
does not appear to be acting as a tumor suppressor in SCC.  In fact, loss of DcpS leads 
to anti-tumorigenic phenotypes such as deceased cell proliferation and induced 
apoptosis.  Based on the results from this study, it seems unlikely that DcpS is 
important in cutaneous squamous cell carcinoma susceptibility, however further studies 
are needed to definitively determine whether these characteristics of DcpS will continue 
to be detected in in vivo studies.  If loss of DcpS does indeed have anti-tumorigenic 
properties, this will be important information for the development of future cancer 
susceptibility screens and therapeutic treatments.  
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